Literature DB >> 12775708

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Lesley-Ann Martin1, Ian Farmer, Stephen R D Johnston, Simak Ali, Chris Marshall, Mitch Dowsett.   

Abstract

The mechanisms involved in resistance to estrogen deprivation are of major importance for optimal patient therapy and the development of new drugs. Long term culture of MCF-7 cells in estrogen (E2)-depleted medium (long term estrogen deprivation; LTED) results in hypersensitivity to E2 coinciding with elevated levels of estrogen receptor (ER) alpha phosphorylated on Ser118 and MAPK, together with several of its downstream targets associated previously with ERalpha phosphorylation. Our data suggest elevated MAPK activity results from enhanced ERBB2 expression in the LTED cells versus the wild-type (wt), and treatment with the tyrosine kinase inhibitor ZD1839 revealed increased sensitivity in both transcription and proliferation assays. Similarly the MEK inhibitor U0126 decreased transcription and proliferation in the LTED cells and reduced their sensitivity to the proliferative effects of E2, while having no effect on the wt. However, the complete suppression of MAPK activity in the LTED cells did not inhibit ERalpha Ser118 phosphorylation suggesting that ER activity remained ligand-dependant. The LTED cells also expressed elevated levels of insulin-like growth factor-1R, and inhibition of phosphatidylinositol 3-kinase activity with LY294002 reduced basal ERalpha transactivation by 70% in the LTED cells compared with the wt. However, LY294002 had no effect on ERalpha Ser118 phosphorylation. These data suggest that although elevated levels of MAPK occur during LTED and influence the phenotype, this is unlikely to be the sole pathway operating to achieve adaptation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775708     DOI: 10.1074/jbc.M305226200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.

Authors:  Bin Su; Xiaohan Cai; Yanyan Hong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-11       Impact factor: 4.292

2.  Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic.

Authors:  Jinghua Gu; Jianhua Xuan; Rebecca B Riggins; Li Chen; Yue Wang; Robert Clarke
Journal:  Bioinformatics       Date:  2012-05-17       Impact factor: 6.937

Review 3.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 4.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

5.  Cadmium alters the reproductive endocrine disruption and enhancement of growth in the early and adult stages of Oreochromis mossambicus.

Authors:  C Amutha; P Subramanian
Journal:  Fish Physiol Biochem       Date:  2012-08-19       Impact factor: 2.794

Review 6.  The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective.

Authors:  A Urruticoechea
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

Review 7.  Fulvestrant and the sequential endocrine cascade for advanced breast cancer.

Authors:  S Johnston
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

8.  EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

Authors:  A H Evans; S Pancholi; I Farmer; A Thornhill; D B Evans; S R Johnston; M Dowsett; L-A Martin
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

9.  Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Authors:  M Hauglid Flågeng; L L Haugan Moi; J M Dixon; J Geisler; E A Lien; W R Miller; P E Lønning; G Mellgren
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

10.  Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

Authors:  I Barone; D Iacopetta; K R Covington; Y Cui; A Tsimelzon; A Beyer; S Andò; S A W Fuqua
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.